Filamin A-bound PEBP2β/CBFβ is retained in the cytoplasm and prevented from functioning as a partner of the Runx1 transcription factor

Molecular and Cellular Biology

Volumn 25, Issue 3, 2005, Pages 1003-1012

  Yoshida, Naomi ^a   Ogata, Takehiro ^a   Tanabe, Kenji ^a   Li, Songhua ^a   Nakazato, Megumi ^a   Kohu, Kazuyoshi ^a   Takafuta, Toshiro ^b   Shapiro, Sandor ^c   Ohta, Yasutaka ^d   Satake, Masanobu ^a   Watanabe, Toshio ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b NISHI KOBE MEDICAL CENTER   (Japan)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ACTIN BINDING PROTEIN; AMINO ACID; FILAMIN; FILAMIN A; PROTEIN SUBUNIT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PEBP2BETA CBFBETA; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; CONTRACTILE PROTEIN; DNA BINDING PROTEIN; FILAMINS; ONCOPROTEIN; RUNX1 PROTEIN, HUMAN; RUNX1 PROTEIN, MOUSE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 2;

ARTICLE; CELL NUCLEUS; CYTOPLASM; GENE DELETION; GENE REPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; ANIMAL; HELA CELL; METABOLISM; MOUSE; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; TWO HYBRID SYSTEM;

ANIMALS; CELL NUCLEUS; CONTRACTILE PROTEINS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYTOPLASM; DNA-BINDING PROTEINS; HELA CELLS; HUMANS; MICE; MICROFILAMENT PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION FACTORS; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 19944431843     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.25.3.1003-1012.2005     Document Type: Article

References (39)

1. Adya, N., T. Stacy, N. A. Speck, and P. P. Liu. 1998. The leukemic protein core binding factor β (CBFβ)-smooth-muscle myosin heavy chain sequesters CBFα2 into cytoskeletal filaments and aggregates. Mol. Cell. Biol. 18:7432-7443.
2. Ahn, M. Y., G. Huang, S. C. Bae, H. J. Wee, W. Y. Kim, and Y. Ito. 1998. Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dc13 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO. Proc. Natl. Acad. Sci. USA 95:1812-1817.
3. Bechtel, P. J. 1979. Identification of a high molecular weight actin-binding protein in skeletal muscle. J. Biol. Chem. 254:1755-1758.
4. Berardi, M. J., C. Sun, M. Zehr, F. Abildgaard, J. Peng, H. A. Speck, and J. H. Bushweller. 1999. The Ig fold of the core binding factor α Runt domain is a member of a family of structurally and functionally related Ig-fold DNA-binding domains. Struct. Fold Des. 7:1247-1256.
5. Bruhn, L., A. Munnerlyn, and R. Grosschedl. 1997. ALY, a context-dependent coactivator of LEF-1 and AML-1, is required for TCR α enhancer function. Genes Dev. 11:640-653.
6. Cai, Z., M. de Bruijn, X. Ma, B. Dortland, T. Luteijn, R. J. Downing, and E. Dzierzak. 2000. Haploinsufficiency of AML1 affects the temporal and spatial generation of hematopoietic stem cells in the mouse embryo. Immunity 13:423-431.
7. Chiba, N., T. Watanabe, S. Nomura, Y. Tanaka, M. Minowa, M. Niki, R. Kanamaru, and M. Satake. 1997. Differentiation dependent expression and distinct subcellular localization of the protooncogene product, PEBP2β/CBFβ, in muscle development. Oncogene 14:2543-2552.
8. Cunningham, C. C., J. B. Gorlin, D. J. Kwiatkowski, J. H. Hartwig, P. A. Janmey, H. R. Byers, and T. P. Stossel. 1992. Actin-binding protein requirement for cortical stability and efficient locomotion. Science 255:325-327.
9. Goger, M., V. Gupta, W. Y. Kim, K. Shigesada, Y. Ito, and M. H. Werner. 1999. Molecular insights into PEBP2/CBFβ-SMMHC associated acute leukemia revealed from the structure of PEBP2/CBFβ. Nat. Struct. Biol. 6:620-623.
10. Gu, T. L., T. L. Goetz, B. J. Graves, and N. A. Speck. 2000. Auto-inhibition and partner proteins, core-binding factor β (CBFβ) and Ets-1, modulate DNA binding by CBFα2 (AML1). Mol. Cell. Biol. 20:91-103.
11. Huang, G., K. Shigesada, K. Ito, H. J. Wee, T. Yokomizo, and Y. Ito. 2001. Dimerization with PEBP2β protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J. 20:723-733.
12. Huang, X., J. W. Peng, N. A. Speck, and J. H. Bushweller. 1999. Solution structure of core binding factor beta and map of the CBF α binding site. Nat. Struct. Biol. 6:624-627.
13. Imai, Y., M. Kurokawa, K. Tanaka, A. D. Friedman, S. Ogawa, K. Mitani, Y. Yazaki, and H. Hirai. 1998. TLE, the human homolog of groucho, interacts with AML1 and acts as a repressor of AML1-induced transactivation. Biochem. Biophys. Res. Commun. 252:582-589.
14. Kanno, T., Y. Kanno, L. F. Chen, E. Ogawa, W. Y. Kim, and Y. Ito. 1998. Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor α subunit revealed in the presence of the β subunit. Mol. Cell. Biol. 18:2444-2454.
15. Kim, W. Y., M. Sieweke, E. Ogawa, H. J. Wee, U. Englmeier, T. Graf, and Y. Ito. 1999. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J. 18:1609-1620.
16. Kitabayashi, I., A. Yokoyama, K. Shimizu, and M. Ohki. 1998. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J. 17:2994-3004.
17. Kitabayashi, I., Y. Aikawa, L. A. Nguyen, A. Yokoyama, and M. Ohki. 2001. Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J. 20:7184-7196.
18. Levanon, D., R. E. Goldstein, Y. Bernstein, H. Tang, D. Goldenberg, S. Stifani, Z. Paroush, and Y. Groner. 1998. Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc. Natl. Acad. Sci. USA 95:11590-11595.
19. Lutterbach, B., J. J. Westendorf, B. Linggi, S. Isaac, E. Seto, and S. W. Hiebert. 2000. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J. Biol. Chem. 275:651-656.
20. Mukouyama, Y., N. Chiba, T. Hara, H. Okada, Y. Ito, R. Kanamaru, A. Miyajima, M. Satake, and T. Watanabe. 2000. The AML1 transcription factor functions to develop and maintain hematogenic precursor cells in the embryonic aorta-gonad-mesonephros region. Dev. Biol. 220:27-36.
21. Nagata, T., V. Gupta, D. Sorce, W. Y. Kim, A. Sali, B. T. Chait, K. Shigesada, Y. Ito, and M. H. Werner. 1999. Immunoglobulin motif DNA recognition and heterodimerization of the PEBP2/CBF Runt domain. Nat. Struct. Biol. 6:615-619.
22. Niki, M., H. Okada, H. Takano, J. Kuno, K. Tani, H. Hibino, S. Asano, Y. Ito, M. Satake, and T. Noda. 1997. Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor. Proc. Natl. Acad. Sci. USA 94:5697-5702.
23. North, T., T. L. Gu, T. Stacy, Q. Wang, L. Howard, M. Binder, M. Marin-Padilla, and N. A. Speck. 1999. Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. Development 126:2563-2575.
24. Okada, H., T. Watanabe, M. Niki, H. Takano, N. Chiba, N. Yanai, K. Tani, H. Hibino, S. Asano, M. L. Mucenski, Y. Ito, T. Noda, and M. Satake. 1998. AML1(-/-) embryos do not express certain hematopoiesis-related gene transcripts including those of the PU.1 gene. Oncogene 17:2287-2293.
25. Okuda, T., J. van Deursen, S. W. Hiebert, G. Grosveld, and J. R. Downing. 1996. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330.
26. Ozanne, D. M., M. E. Brady, S. Cook, L. Gaughan, D. E. Neal, and C. N. Robson. 2000. Androgen receptor nuclear translocation is facilitated by the F-actin cross-linking protein filamin. Mol. Endocrinol. 14:1618-1626.
27. Sasaki, A., Y. Masuda, Y. Ohta, K. Ikeda, and K. Watanabe. 2001. Filamin A associates with Smads and regulates transforming growth factor-β signaling. J. Biol. Chem. 276:17871-17877.
28. Sasaki, K., H. Yagi, R. T. Bronson, T. K. Tominaga, T. Matsunashi, K. Deguchi, Y. Tani, T. Kishimoto, and T. Komori. 1996. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor β. Proc. Natl. Acad. Sci. USA 93:12359-12363.
29. Stossel, T. P., J. Condeelis, L. Cooley, J. H. Hartwig, A. Noegel, M. Schleicher, and S. S. Shapiro. 2001. Filamins as integrators of cell mechanics and signalling. Nat. Rev. Mol. Cell Biol. 2:138-145.
30. Tahirov, T. H., T. Inoue-Bungo, H. Morii, A. Fujikawa, M. Sasaki, K. Kimura, M. Shiina, K. Sato, T. Kumasaka, M. Yamamoto, S. Ishii, and K. Ogata. 2001. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFβ. Cell 104:755-767.
31. Tanaka, K., T. Tanaka, M. Kurokawa, Y. Imai, S. Ogawa, K. Mitani, Y. Yazaki, and H. Hirai. 1998. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2β (CBFβ) in the nucleus more efficiently than wild-type AML1. Blood 91:1688-1699.
32. Tanaka, Y., T. Watanabe, N. Chiba, M. Niki, Y. Kuroiwa, T. Nishihira, S. Satomi, Y. Ito, and M. Satake. 1997. The protooncogene product, PEBP2β/CBFβ, is mainly located in the cytoplasm and has an affinity with cytoskeletal structures. Oncogene 15:677-683.
33. Tanaka, Y., M. Fujii, K. Hayashi, N. Chiba, T. Akaishi, R. Shineha, T. Nishihira, S. Satomi, Y. Ito, T. Watanabe, and M. Satake. 1998. The chimeric protein, PEBP2β/CBFβ-SMMHC, disorganizes cytoplasmic stress fibers and inhibits transcriptional activation. Oncogene 17:699-708.
34. Wang, Q., T. Stacy, M. Binder, M. Marin-Padilla, A. H. Sharpe, and N. A. Speck. 1996. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl. Acad. Sci. USA 93:3444-3449.
35. Wang, Q., T. Stacy, J. D. Miller, A. F. Lewis, T. L. Gu, X. Huang, J. H. Bushweller, J. C. Bories, F. W. Alt, G. Ryan, P. P. Liu, A. Wynshaw-Boris, M. Binder, M. Marin-Padilla, A. H. Sharpe, and N. A. Speck. 1996. The CBFβ subunit is essential for CBFα2 (AML1) function in vivo. Cell 87:697-708.
36. Warren, A. J., J. Bravo, R. L. Williams, and T. H. Rabbitts. 2000. Structural basis for the heterodimeric interaction between the acute leukaemia-associated transcription factors AML1 and CBFβ. EMBO J. 19:3004-3015.
37. Yagi, R., L. F. Chen, K. Shigesada, Y. Murakami, and Y. Ito. 1999. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J. 18:2551-2562.
38. Zaidi, S. K., A. J. Sullivan, R. Medina, Y. Ito, Y. J. Van Wijnen, J. L. Stein, J. B. Lian and G. S. Stein. 2004. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J. 23:790-799.
39. Zhang, D. E., C. J. Hetherington, S. Meyers, K. L. Rhoades, C. J. Larson, H. M. Chen, S. W. Hiebert, and D. G. Tenen. 1996. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF α2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol. Cell. Biol. 16:1231-1240.